Tempus AI's growth is fueled by data services and acquisitions, despite financial risks. Key Q2 results may shape its path to ...

Tempus AI's growth in precision oncology drives an 80% revenue boost by 2025. Click here to find out why I rate TEM stock a ...

Tempus AI Inc (NASDAQ:TEM) shares are trading higher Wednesday after the company announced that it received 510(k) clearance ...

Tempus AI and NVIDIA are both actively working at the intersection of AI and healthcare. Tempus AI, while advancing precision ...

Given the company’s popularity among hedge funds and the bullish sentiment surrounding it, Tempus AI, Inc. (NASDAQ:TEM) makes ...

TEM stock rallies 7.3% after the FDA clears its second cardiology AI tool, witnessing a 48% surge in just three months.

AI Stocks are leading the next wave of tech innovation, from chipmakers to healthcare and voice tech.SoundHound stock has gained over 125% in 202 ...

This marks the second FDA-cleared ECG-AI device in Tempus’ cardiovascular product suite, following its previously cleared Tempus ECG-AF solution. The new software analyzes resting, non-ambulatory ...

Tempus AI is a growth stock that is down 31% from all-time highs. Here's why TEM AI stock could be a part of your TFSA ...

Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting ...

Recognizing that breast cancer guidelines, much like those for lung cancer, are constantly evolving, Tempus is working to ...

Following closely was ARK’s investment in Tempus AI Inc (TEM), where the firm bought 158,051 shares across its ARKK and ARKG ETFs, totaling $8,833,470. This purchase continues a recent trend of ARK ...